Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo
批准号:
7908892
负责人:
Bruce S Bochner
金额:
$39.82万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-06-15 至 2012-05-31
关键词:
AffinityAgonistAllergicAllergic inflammationAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntigensApoptosisBasophilsBindingBiologicalBloodBone MarrowCarbohydratesCaspaseCell LineCell Surface ReceptorsCell physiologyCellsChimeric ProteinsCollaborationsComplexCytology HistologyCytoplasmic TailDataDatabasesDiseaseDoseDrug or chemical Tissue DistributionEffector CellEnzymesEpitopesEventExtracellular DomainFamilyGlycolipidsGlycoproteinsHumanImmunoglobulinsImmunosuppressionIn VitroInflammatoryInflammatory ResponseInorganic SulfatesIntegral Membrane ProteinInterleukin-13Interleukin-5Knockout MiceLaboratoriesLeadLectinLigandsLungMediator of activation proteinModelingMonitorMonoclonal AntibodiesMusNADPH OxidaseOrthologous GenePTPN6 genePhosphoric Monoester HydrolasesPhysiologyPoint MutationPolysaccharidesRegulationReportingResearch PersonnelResistanceResolutionRoleSialic AcidsSignal PathwaySignal TransductionSourceSpecificityStructureSurfaceTestingTherapeuticTherapeutic EffectTissuesTransgenic OrganismsTransmembrane DomainType I Epithelial Receptor CellTyrosineUnspecified or Sulfate Ion SulfatesWorkallergic responsebasecrosslinkeosinophilextracellulargastrointestinal epitheliumhuman SIGLEC8 proteinin vivokeratan sulfate Gal-6-sulfotransferasemast cellmembermimeticsmouse modelnovelnovel therapeutic interventionparalogous geneprogramsreceptor bindingresearch studyresponsesialic acid binding Ig-like lectin
中文摘要
描述(申请人提供):Siglec-8是CD33唾液酸结合免疫球蛋白样凝集素(Siglec)家族的成员,仅在人类肥大细胞、嗜酸性粒细胞和嗜碱性粒细胞上发现。这种跨膜蛋白具有识别特定碳水化合物分子(多糖)的胞外结构域,以及基于酪氨酸的细胞内抑制基序,可以将受体结合转化为免疫抑制。小鼠Siglec-F和人类Siglec-8是功能趋同的对虾。小鼠Siglec-F主要表达在小鼠嗜酸性粒细胞上。人的嗜酸性粒细胞与特定的Siglec-8抗体孵育,或小鼠的嗜酸性粒细胞与Siglec-F抗体孵育,诱导细胞凋亡,给小鼠注射Siglec-F抗体可减少嗜酸性粒细胞的数量。相反,Siglec-8在体外被抗体结合到人肥大细胞上不会诱导细胞凋亡,但会抑制通过FceRI激活而诱导的介质释放。Siglec-8和Siglec-F都结合一种独特的糖链配体,称为6‘-磺酸-SLeX或NeuAca2-3(6-O-Sulo)Ga1S1-4[Fuca1-3]G1cNAc。因此,通过Siglec-8/Siglec-F的天然糖链配体,或通过抗体或拟糖激动剂激活Siglec-8/Siglec-F,可能提供一种新的方法来特异性地抑制和/或耗尽嗜酸性粒细胞和肥大细胞,从而减少过敏性炎症反应。因此,我们假设:(I)过敏性炎症细胞表面的Siglec-8/Siglec-F与其在组织上表达的天然碳水化合物配体结合,通过激活负信号通路来限制过敏性炎症;(Ii)体内的过敏性炎症可以通过调节天然Siglec-8配体在组织中的表达来控制;以及(Iii)Siglec-8/Siglec-F单抗或基于其配体结构的合成分子(糖类模拟)将能够阻断过敏性炎症。这些概念将通过四个具体目标进行探讨。目的1鉴定天然Siglec-8/Siglec-F配体并测定其组织表达。目的2确定Siglec-8/Siglec-F配体模拟物在体外限制嗜酸性粒细胞和肥大细胞过敏反应的能力。目的3将探讨单抗或配体模拟物在体内限制过敏反应的能力,目的4将确定Siglec-8参与诱导嗜酸性粒细胞凋亡和抑制肥大细胞介质释放的机制。我们关于Siglec-8/Siglec-F的拟议工作应该确定新的治疗方法,用于治疗以嗜酸性粒细胞、嗜碱性粒细胞和肥大细胞数量增加或介体增加为特征的疾病。
英文摘要
DESCRIPTION (provided by applicant): Siglec-8 is a member of the CD33 sialic acid-bind immunoglobulin-like lectin (Siglec) family found only on human mast cells, eosinophils and basophils. This transmembrane protein has an extracellular domain that recognizes specific carbohydrate molecules (glycans), and intracellular tyrosine-based inhibition motifs that putatively converts receptor binding into immune suppression. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs. Mouse Siglec-F is expressed predominantly on mouse eosinophils. Incubation of human eosinophils with specific Siglec-8 antibodies, or mouse eosinophils with Siglec-F antibodies, induces apoptosis, and dosing of mice with Siglec-F antibodies reduces eosinophil numbers. In contrast, Siglec-8 engagement on human mast cells by antibodies in vitro does not induce apoptosis but does inhibit mediator release induced via FceRI activation. Both Siglec-8 and Siglec-F bind a unique glycan ligand referred to as 6'-sulfo-sLex, or NeuAca2-3(6-O-sulfo)Ga1S1-4[Fuca1-3]G1cNAc. Therefore, activation of Siglec-8/Siglec-F through its natural glycan ligand, or through antibodies or glycomimetic agonists, may provide a novel means to specifically inhibit and/or deplete eosinophils and mast cells, thereby reducing allergic inflammatory responses. We thus hypothesize that: (i) Siglec-8/Siglec-F on the surface of allergic inflammatory cells binds to its natural carbohydrate ligands, expressed on tissues, to limit allergic inflammation by activating a negative signaling pathway; (ii) Allergic inflammation in vivo can be controlled by regulating expression of natural Siglec-8 ligands in tissues; and (iii) Siglec-8/Siglec-F mAbs or synthetic molecules based on the structure of their ligands (glycomimetics) will be capable of interrupting allergic inflammation. These concepts will be explored through four specific aims. Aim 1 will characterize natural Siglec-8/Siglec-F ligands and determine their tissue expression. Aim 2 will determine the ability of Siglec- 8/Siglec-F ligand mimetics to limit allergic responses in eosinophils and mast cells in vitro. Aim 3 will explore the ability of mAbs or ligand mimetics to limit allergic responses in vivo, and Aim 4 will identify mechanisms by which Siglec-8 engagement induces eosinophil apoptosis and inhibits mast cell mediator release. Our proposed work on Siglec-8/Siglec-F should identify new therapeutic approaches for the treatment of diseases characterized by increased numbers of, or mediators from, eosinophils, basophils and mast cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
-
批准号:10194041
-
项目类别:
-
资助金额:$18.67万
-
财政年份:2021
-
负责人:Bruce S Bochner
-
依托单位:
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
-
批准号:10368109
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2021
-
负责人:Bruce S Bochner
-
依托单位:
Using siglecs and their ligands to treat allergic diseases SALTAD
-
批准号:10331722
-
项目类别:
-
资助金额:$150.57万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases
-
批准号:10097994
-
项目类别:
-
资助金额:$42.29万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Core A Admin
-
批准号:10331723
-
项目类别:
-
资助金额:$2.54万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Core A Admin
-
批准号:10097991
-
项目类别:
-
资助金额:$2.77万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Using siglecs and their ligands to treat allergic diseases SALTAD
-
批准号:10097976
-
项目类别:
-
资助金额:$151.6万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases
-
批准号:10331725
-
项目类别:
-
资助金额:$38.76万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Human mast cell and tissue acquisition core
-
批准号:10331724
-
项目类别:
-
资助金额:$12.29万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Human mast cell and tissue acquisition core
-
批准号:10097992
-
项目类别:
-
资助金额:$13.44万
-
财政年份:2018
-
负责人:Bruce S Bochner
-
依托单位:
Northwestern University Allergy and Immunology Research (NUAIR) Program
-
批准号:10207416
-
项目类别:
-
资助金额:$31.15万
-
财政年份:2010
-
负责人:Bruce S Bochner
-
依托单位:
Northwestern University Allergy and Immunology Research (NUAIR) Program
-
批准号:10403967
-
项目类别:
-
资助金额:$24.85万
-
财政年份:2010
-
负责人:Bruce S Bochner
-
依托单位:
Northwestern University Allergy and Immunology Research (NUAIR) Program
-
批准号:10020716
-
项目类别:
-
资助金额:$29.71万
-
财政年份:2010
-
负责人:Bruce S Bochner
-
依托单位:
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo
-
批准号:8075272
-
项目类别:
-
资助金额:$23.29万
-
财政年份:2010
-
负责人:Bruce S Bochner
-
依托单位:
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo
-
批准号:7446730
-
项目类别:
-
资助金额:$40.22万
-
财政年份:2007
-
负责人:Bruce S Bochner
-
依托单位:
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo
-
批准号:7315800
-
项目类别:
-
资助金额:$40.99万
-
财政年份:2007
-
负责人:Bruce S Bochner
-
依托单位:
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
-
批准号:8804904
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:Bruce S Bochner
-
依托单位:
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In Vivo
-
批准号:8075586
-
项目类别:
-
资助金额:$39.42万
-
财政年份:2007
-
负责人:Bruce S Bochner
-
依托单位:
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
-
批准号:8698832
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2007
-
负责人:Bruce S Bochner
-
依托单位:
Targeting Siglec-8/-F to treat eosinophil and mast cell related disorders
-
批准号:8500954
-
项目类别:
-
资助金额:$3.7万
-
财政年份:2007
-
负责人:Bruce S Bochner
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: